NEW YORK (Standard&Poor's) Oct. 22, 2015--Standard&Poor's Ratings Services said today that market speculation about potential fraud by Valeant Pharmaceuticals International Inc. in a research firm's report and a sharp decline in the common shares of Valeant do not affect its ratings or outlook on the company. We don't see the facts and reasoning in the research report as supporting evidence of the allegations of falsified invoices or channel stuffing. For these reasons, and given company comments to the contrary, we view these assertions as unfounded. We see some incremental downside risk following the increased attention to the company's usage of specialty pharmacies for distribution, given the advantages of using these channels. We will continue to monitor
